Article
DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation
10 May 2023
Abstract excerpt
Hematopoietic stem cell transplantation (HSCT) represents the standard treatment for patients with high or intermediate-2 risk (IPSS classification) myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with intermediate or unfavorable risk (ELN classification) [ 1 ]. Despite recent progress in both induction treatment as well as conditioning regimens before transplantation and immunosuppression...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
